【摘要】：目的：本研究的目的是確定和分析非小細(xì)胞肺癌(NSCLC)的中醫(yī)辯證、治療原則及常用中藥、包括年齡、性別、職業(yè)、相關(guān)疾病、家族史、病理分期和腫瘤標(biāo)志物。材料于方法：按標(biāo)準(zhǔn)納入與排除、收集2015年5月～2015年12月于江蘇省中醫(yī)院住院的非小細(xì)胞肺癌病例115例。隨著這項研究專門設(shè)計的形式幫助收集的數(shù)據(jù)進(jìn)行分析、利用SPSS 21和Excel統(tǒng)計軟件。結(jié)果：研究數(shù)的分析顯示115例(非小細(xì)胞肺癌)中、男性64例、女性51例、平均年齡64.42±8.76歲。男女之比為1.25：1。其中79例患者無吸煙史(68.7%)、36例患者有吸煙史(31.3%)。非小細(xì)胞肺癌的發(fā)病率最高的年齡組61-70歲；共47例(40.9%)。共計六個證候、四個虛證、兩個實證。夾雜證候為特征、沒有單一證型。62.6%氣陰兩虛、25.2%脾肺兩虛、5.2%氣滯血瘀、2.6%肺腎氣虛、2.6%痰濕壅肺、1.7%氣血兩虛。證候性質(zhì)在不同臨床分期與非小細(xì)胞肺癌不同病理亞型幾乎相同。通過數(shù)據(jù)分析總結(jié)出17種不同的治法、9個治法用于治療氣陰兩虛證候、而4個治法用于治療脾肺兩虛證候。115例非小細(xì)胞肺癌患者的治療中、共用223個藥物、包括草藥、動物藥及礦物質(zhì)。其中、204種草藥、14種動物藥和5種礦物藥。肺腎兩虛與腫瘤標(biāo)志物CEA、CA125、CA199對比經(jīng)統(tǒng)計學(xué)比較有差異(P0.05)。結(jié)論：共有6個證候、氣陰兩虛、脾肺兩虛、氣滯血瘀、肺腎兩虛、痰濕壅肺、氣血兩虛。為管理這些綜合征的非小細(xì)胞肺癌患者中、共17的治療原則是采用223味藥物包括204種不同的中藥材、14種不同的動物產(chǎn)品、和5種不同的礦物。
[Abstract]:Objective: the purpose of this study was to determine and analyze the traditional Chinese medicine (TCM) dialectical, therapeutic principles and traditional Chinese medicine for (NSCLC), including age, sex, occupation, related diseases, family history, pathological stages and tumor markers. Materials and methods: 115 cases of non-small cell lung cancer (NSCLC) hospitalized in Jiangsu Provincial Hospital of traditional Chinese Medicine from May 2015 to December 2015 were collected and excluded according to the standard. Along with the study's specially designed form to help collect data for analysis, use SPSS 21 and Excel statistical software. Results: there were 115 cases of non-small cell lung cancer (NSCLC), 64 males and 51 females with an average age of 64.42 鹵8.76 years. The ratio of men to women is 1.25: 1. Among them, 79 patients had no smoking history (68.7%) and 36 patients had smoking history (31.3%). The highest incidence of non-small cell lung cancer (NSCLC) was 61-70 years old in 47 cases (40.9%). A total of six syndromes, four deficiency syndrome, two empirical evidence. There was no single syndrome type. 62.6% Qi and Yin deficiency was 25.2% spleen and lung deficiency was 5.2% Qi stagnation and blood stasis was 2.6% phlegm dampness in lung was 1.7% qi and blood deficiency. The syndromes were almost the same in different clinical stages and different pathological subtypes of non-small cell lung cancer (NSCLC). Through data analysis, 17 different treatment methods were summarized, 9 were used to treat Qi and Yin deficiency syndrome, and 4 were used to treat spleen and lung deficiency syndrome. 115 patients with non-small cell lung cancer were treated with 223 drugs, including herbal medicine. Animal medicine and minerals. There are 204 kinds of herbs, 14 kinds of animal medicine and 5 kinds of mineral medicine. There was significant difference between lung and kidney deficiency and tumor marker CEA CA125, CA199 (P0.05). Conclusion: there are 6 syndromes: deficiency of qi and yin, deficiency of spleen and lung, stagnation of qi and blood stasis, deficiency of lung and kidney, phlegm and dampness of lung, deficiency of qi and blood. In order to manage these syndromes in non-small cell lung cancer patients, a total of 17 treatment principle is to use 223 drugs, including 204 different kinds of traditional Chinese medicine, 14 different animal products, and 5 different minerals.
【學(xué)位授予單位】：南京中醫(yī)藥大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2016
【分類號】：R273

【參考文獻(xiàn)】

相關(guān)期刊論文 前1條

1 吳繼;徐振曄;王中奇;周衛(wèi)東;鄧海濱;趙曉珍;白冰;王立芳;;抗瘤增效方治療晚期非小細(xì)胞肺癌的臨床研究[J];中國中西醫(yī)結(jié)合雜志;2010年02期

，

本文編號：2139445